Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedAug 10, 2025
DataAggregated Company Financials
Companies8
- 7D7.4%
- 3M48.7%
- 1Y41.3%
- YTD49.0%
In the last week, the Life Sciences industry is up 7.4%, with Oxford Nanopore Technologies up 7.8%. During this same period, the Oxford BioDynamics underperformed, falling 17%. This takes the industry's 12 month performance to a gain of 41%. As for the next few years, earnings are expected to grow by 34% per annum.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 10 Aug 2025 | UK£2.3b | UK£291.9m | -UK£160,968,352.00 | 6.9x | -14.3x | 7.9x |
| Tue, 08 Jul 2025 | UK£1.6b | UK£291.9m | -UK£160,968,352.00 | 6.6x | -9.8x | 5.4x |
| Thu, 05 Jun 2025 | UK£1.6b | UK£319.4m | -UK£190,791,730.00 | 6.6x | -8.1x | 4.9x |
| Sat, 03 May 2025 | UK£1.7b | UK£314.0m | -UK£192,459,514.70 | 11.3x | -8.7x | 5.3x |
| Mon, 31 Mar 2025 | UK£1.5b | UK£315.7m | -UK£186,460,928.95 | 5.5x | -7.9x | 4.7x |
| Wed, 26 Feb 2025 | UK£1.6b | UK£306.4m | -UK£195,093,302.64 | 6.2x | -8.4x | 5.3x |
| Fri, 24 Jan 2025 | UK£2.1b | UK£307.2m | -UK£195,788,725.20 | 7.7x | -10.6x | 6.8x |
| Sun, 22 Dec 2024 | UK£2.0b | UK£306.6m | -UK£195,263,763.36 | 7.7x | -10.2x | 6.5x |
| Tue, 19 Nov 2024 | UK£1.8b | UK£305.8m | -UK£193,578,219.28 | 9.9x | -9.2x | 5.8x |
| Thu, 17 Oct 2024 | UK£2.0b | UK£304.6m | -UK£192,522,726.70 | 11.5x | -10.4x | 6.6x |
| Sat, 14 Sep 2024 | UK£2.0b | UK£301.9m | -UK£190,970,145.50 | 11x | -10.6x | 6.7x |
| Mon, 12 Aug 2024 | UK£1.8b | UK£296.8m | -UK£189,164,393.70 | 12.3x | -9.6x | 6.1x |
| Wed, 10 Jul 2024 | UK£1.5b | UK£295.6m | -UK£189,989,628.63 | 11.5x | -8.1x | 5.2x |
| Fri, 07 Jun 2024 | UK£1.6b | UK£295.5m | -UK£189,707,628.63 | 11.4x | -8.3x | 5.4x |
| Sun, 05 May 2024 | UK£1.6b | UK£292.8m | -UK£188,897,474.93 | 6902.8x | -8.3x | 5.3x |
| Tue, 02 Apr 2024 | UK£1.7b | UK£319.1m | -UK£191,419,403.70 | 69.8x | -9.1x | 5.5x |
| Thu, 29 Feb 2024 | UK£1.9b | UK£285.8m | -UK£189,230,023.72 | 6787x | -9.9x | 6.5x |
| Sat, 27 Jan 2024 | UK£2.7b | UK£450.2m | -UK£176,590,140.00 | 65.1x | -15.3x | 6x |
| Mon, 25 Dec 2023 | UK£3.1b | UK£450.0m | -UK£174,026,893.00 | 52.7x | -18.1x | 7x |
| Wed, 22 Nov 2023 | UK£3.0b | UK£455.6m | -UK£168,678,421.00 | 49.9x | -17.9x | 6.6x |
| Fri, 20 Oct 2023 | UK£3.1b | UK£458.7m | -UK£165,682,864.00 | 48.9x | -18.5x | 6.7x |
| Sun, 17 Sep 2023 | UK£3.1b | UK£440.6m | -UK£167,135,947.00 | 67.5x | -18.8x | 7.1x |
| Tue, 15 Aug 2023 | UK£3.2b | UK£476.2m | -UK£126,577,489.00 | 70.6x | -25.6x | 6.8x |
| Thu, 13 Jul 2023 | UK£3.1b | UK£475.9m | -UK£124,244,334.00 | 66.1x | -24.7x | 6.5x |
| Sat, 10 Jun 2023 | UK£3.2b | UK£476.9m | -UK£125,014,596.00 | 63.5x | -25.5x | 6.7x |
| Mon, 08 May 2023 | UK£3.2b | UK£479.8m | -UK£117,065,248.00 | 36.3x | -26.9x | 6.6x |
| Wed, 05 Apr 2023 | UK£3.0b | UK£458.5m | -UK£118,906,371.00 | 35.7x | -24.9x | 6.5x |
| Fri, 03 Mar 2023 | UK£3.0b | UK£444.0m | -UK£183,288,466.00 | 43.6x | -16.6x | 6.9x |
| Sun, 29 Jan 2023 | UK£3.4b | UK£442.7m | -UK£182,570,410.00 | 45.3x | -18.7x | 7.7x |
| Tue, 27 Dec 2022 | UK£3.4b | UK£443.7m | -UK£183,037,688.00 | 49.1x | -18.4x | 7.6x |
| Thu, 24 Nov 2022 | UK£3.6b | UK£446.8m | -UK£179,125,816.00 | 49.9x | -20.1x | 8.1x |
| Sat, 22 Oct 2022 | UK£3.4b | UK£449.3m | -UK£176,581,530.00 | 42.2x | -19.3x | 7.6x |
| Mon, 19 Sep 2022 | UK£3.8b | UK£429.9m | -UK£176,728,781.00 | 44.9x | -21.2x | 8.7x |
| Wed, 17 Aug 2022 | UK£4.0b | UK£368.6m | -UK£191,230,554.00 | 50.2x | -20.9x | 10.9x |
Price to Earnings Ratio
-20.9x
Current Industry PE
- Investors are relatively neutral on the British Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 7.7x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 7.5% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | 3.24% | |
| Healthcare | -0.94% | |
| Life Sciences | 7.42% | |
| Clinical Research and Equipment | 7.42% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£2.15 | 7.8% +UK£149.1m | 78.9% | PS11.3x | |
| HVO hVIVO | UK£0.11 | 8.5% +UK£5.8m | -62.8% | PE6.9x | |
| FAB Fusion Antibodies | UK£0.14 | 27.3% +UK£3.4m | 359.0% | PS8.8x | |
| DXRX Diaceutics | UK£1.38 | 3.0% +UK£3.4m | 15.5% | PS3.6x |